SCHEMBL734814

SCHEMBL734814

C[C@H](Nc1cccc(OC(F)(F)F)c1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
EPHX2 P34913 1/20 0.48
ALDH1A1 P00352 1/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
HTT P42858 1/20 0.48
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
P2RX1 P51575 1/20 0.47
KIF11 P52732 1/20 0.45
KDM4E B2RXH2 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
GPR139 Q6DWJ6 1/20 0.45
KCNK3 O14649 2/20 0.44
KCNK9 Q9NPC2 2/20 0.44
HDAC8 Q9BY41 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL734815 1.00 NPC1 (0.49) NPC1RAB9AEPHX2ALDH1A1GAA
SCHEMBL3459396 0.87 NPC1 (0.48) NPC1RAB9AEPHX2ALDH1A1GAA
SCHEMBL2339653 0.83 LMNA (0.49) NPC1RAB9AEPHX2ALDH1A1GAA
SCHEMBL26616883 0.82 MTNR1B (0.57) NPC1RAB9AALDH1A1MAPTTSHR
SCHEMBL7717477 0.82 EPHX2 (0.56) EPHX2ALDH1A1GAAMAPTHPGD
SCHEMBL6274304 0.82 MTNR1B (0.57) NPC1RAB9AALDH1A1MAPTTSHR
SCHEMBL7717474 0.82 EPHX2 (0.56) EPHX2ALDH1A1GAAMAPTHPGD
SCHEMBL21571874 0.82 NPC1 (0.46) NPC1RAB9AEPHX2ALDH1A1GAA
SCHEMBL19707830 0.81 GPR139 (0.52) NPC1RAB9ASMN1; SMN2GPR139HDAC8
Hydrochloric Acid SCHEMBL7704862 0.81 EPHX2 (0.54) EPHX2ALDH1A1GAAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102112451-B Diazepan and piperazine derivatives modulators of chemokine receptors HOFFMANN LA ROCHE 2014-01-22 CN disclosed
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
CN-102112451-A Diazepan and piperazine derivatives modulators of chemokine receptors HOFFMANN LA ROCHE 2011-06-29 CN disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 NPC1 1237/4885RAB9A 762/4885EPHX2 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.